The specific objectives of this funding opportunity are to:

• Provide postdoctoral trainees in the field of human genetics and bioinformatics with the opportunity to utilize large-scale genomic and clinical data from CGEn’s HostSeq Databank to support their research;
• Generate rapid knowledge using the HostSeq data to contribute to the current COVID-19 response;
• Raise awareness among postdoctoral trainees of the benefits of genomic and health data sharing and best practices, in particular the FAIR principles (Findability, Accessibility, Interoperability, and Reuse of digital assets), to promote their integration in their work;
• Build capacity to enhance pandemic preparedness and other genomic medicine applications;
• Apply an open science approach to ensure that research findings and other outputs are made available, freely and openly, to the scientific community to accelerate research translation and benefits; and
• Increase capacity and diversity in health data science leading to the establishment of the required infrastructure to fully realize the benefits of an equitable learning health system, by encouraging a diversity of applicants.

As the largest non-governmental funder of inflammatory bowel disease (IBD) research in Canada, Crohn’s and Colitis Canada proudly celebrates and recognizes Canadian IBD researchers for their exceptional contributions to the field of IBD research through four awards. 

Nominations are being accepted until August 15, 2022 at 5 PM ET.

• The Research Leadership Award recognizes an individual who demonstrates leadership in the field of IBD research, significantly contributes to advancing Crohn’s and colitis research in Canada, and makes exceptional contributions to Crohn’s and Colitis Canada’s mission and promise. The recipient will be invited to present their research at the annual Meeting of the Minds conference. Registration, hotel and travel covered by Crohn’s and Colitis Canada.

• The Rising Star Award recognizes the basic or clinical research accomplishments of an outstanding emerging investigator, within five years of their first faculty appointment. The recipient is an innovative leader who advances Crohn's and colitis research in Canada, and has made an outstanding contribution to Crohn’s and Colitis Canada’s mission. The recipient will be invited to present their research at the annual Meeting of the Minds conference. Registration, hotel and travel covered by Crohn’s and Colitis Canada.

Crohn’s and Colitis Canada and Pfizer Canada’s Women in IBD Awards provide research program funding to recognize women of influence who are making outstanding contributions to the field of IBD research.

• The Outstanding Researcher Award recognizes an exceptional female IBD basic or clinical researcher who has been an inspirational leader and role model in the field of IBD research, and contributed significantly to advancing Crohn’s and Colitis Canada’s mission. The recipient will receive $25,000 to support their IBD research program. 

• The Emerging Researcher Award acknowledges the basic or clinical research accomplishments of a junior/newly emerging female IBD researcher, within 5 years of their first faculty appointment, who has shown creativity, initiative and commitment to advancing IBD research and quality of patient care in Canada. The recipient will receive $15,000 to support their IBD research program. 

We encourage you to nominate your IBD colleagues for these research awards to recognize their contributions to the Canadian IBD research landscape. Self-nominations are accepted.

For more information, or to submit a nomination form, visit the Crohn's and Colitis Canada website.

If you are interested in being nominated for one of these awards, please contact Dr. Batia Stolar, Associate Vice-President, Research & Graduate Studies at avp.research@lakeheadu.ca.

The Chan Zuckerberg Initiative invites applications for the second of three cycles for 18-month projects focused on advancing tools and resources that make it possible to gain greater insights into health and disease from single-cell biology datasets.

CMC Microsystems recognizes excellence in Canadian micro-nano research by Canada’s National Design Network through its annual Douglas R. Colton award. Established in honour of the founding president of CMC Microsystems, this award includes a medal and a monetary prize of $4,500.

Faculty, students or alumni who have successfully completed a Master’s or PhD degree in a Canadian university within the previous three calendar years are eligible for this award.

If you are interested in being nominated for this award, please contact Dr. Batia Stolar, Associate Vice-President, Research and Graduate Studies, at  avp.research@lakeheadu.ca.

The Alzheimer's Drug Discovery Foundation (ADDF) and Harrington Discovery Institute provide funding and drug development support of research efforts that aim to treat or prevent Alzheimer’s disease, related dementias and cognitive-decline associated with aging. Each year up to two ADDF-Harrington Scholars are chosen. The award includes:

• Two-year grant
• Funding up to $600,000
• Drug development expertise and project management support
• A personalized team of drug developers and project manager for each award recipient
• Expert business, commercialization and clinical development advice
• Regulatory assistance
• Intellectual property (IP) review and advice
• Assistance identifying and securing additional financial support based on project needs

For more information, please contact Jill Sherman, International Research Facilitator, at intl.research@lakeheadu.ca.

The Warren Alpert Foundation Prize recognizes one or more scientists whose scientific achievements have led to the prevention, cure, or treatment of human disorders or for seminal research that holds great promise to change our ability to treat disease.

If you are interested in being nominated for this award, please contact Dr. Batia Stolar, Associate Vice-President, Research and Graduate Studies, at  bstolar@lakeheadu.ca.

CQDM’s Quantum Leap pharma-led funding program for drug discovery research helps SMEs or Canadian universities achieve innovative translational biopharmaceutical research projects. Projects selected as part of the Quantum Leap program focus on developing cutting-edge technologies with the potential to significantly advance the R&D activities of CQDM’s pharmaceutical members. Quantum Leap projects are executed in close collaboration and with the expert support and funds of pharmaceutical members.

The enabling technologies, innovative platforms and/or innovative therapies derived from the Quantum Leap pharma-led funding program for drug discovery research are selected for their potential to significantly improve, facilitate and/or accelerate the drug discovery process and the development of safer and more effective drugs. The technologies of interest can be at any stage of the drug development process and involve a wide range of therapeutic indications.

Projects are associated with specific deliverables and must be ready for use by CQDM pharmaceutical members upon completion. For scientists, the funded research opens new collaboration opportunities with world-class stakeholders in the industry.